N-Acetyl-L-Leucine
Ataxia-Telangiectasia (A-T)
IntraBio IncPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ataxia-Telangiectasia (A-T) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Conjugated Pneumococcal Vaccine Institute of Child Health | Phase 3 | BB |
TAMOXIFEN Dana-Farber Cancer Institute | Phase 2 | CCC |
EXEMESTANE Dana-Farber Cancer Institute | Phase 2 | CCC |
N-ACETYL LEUCINE | D | |
Induced pluripotent stem cells (iPSCs) Johns Hopkins University | N/A | D |
Mbm-01 Matrix Biomed, Inc. | Phase 2 | NR |
Same molecule, other indications
N-Acetyl-L-Leucine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →